EGFR Mutation Analysis by ARMS PCR Test Cost & Procedure

What accomplishes EGFR Mutation Analysis by ARMS PCR for stratifying NSCLC patients entail?

Allele title: Epidermal Growth Factor Receptor (EGFR). The tumor tissue that has Non-Small Cell Lung Cancer is the subject of this analysis. This test is used to determine whether the EGFR gene has undergone any alterations in lung cancer tumor tissue. The patient will receive a lung cancer trance with the findings. Because obtaining tumor tissue by a biopsy hurts the patient, this test analyses blood plasma rather than tumor tissue.

EGFR Mutation Analysis by ARMS PCR Preparation for Stratifying Patients with NSCLC Examination

These patients' plasma specimens will be acquired for testing. This examination will pertain to patients who originally answered to EGFR TKI therapy but later formulated resistance to it.

Stratifying people with NSCLC utilizing EGFR Mutation Analysis by ARMS PCR

The purpose of the test is to locate any mutations that prevent the medication from suppressing the cancer-causing effects of the EGFR gene. The patient won't experience biopsy pain because this approach does not require tumor tissue.

Method for stratifying individuals with NSCLC who have EGFR mutations using ARMS PCR Test

The individual plasma specimens will be analyzed utilizing the ARMS (amplification refractory mutation systems) and PCR (polymerase chain reaction) techniques. Only accredited medical laboratories will perform the examination. To discover the antagonism mutation in the EGFR allele, lab workers examine specimens taken before and after providing medicines under targeted treatment. Established on this, the patient will obtain additional treatment.

Limitations of the EGFR Mutation Analysis by ARMS PCR for NSCLC

Patient Stratification was responsible for creating this test and determining its performance parameters. The US Food and Drug Administration has not vacated it or provided its approval (FDA).

Prerequisites for Specimens

Also suitable are formalin-fixed paraffin blocks and specimen FNA.

• Volume
• Four slides (4- to 5-micron thick sections)
• Container
• The paraffin block

Advantages of using ARMS PCR and EGFR Mutation Analysis to categorise NSCLC patients:

Finding the mutations that prevent drugs from working on the EGFR gene to lower cancer risk is the aim of the test.

With this technology, tumour tissue is not necessary, so the patient won't feel any pain during the biopsy.